OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 256.97%871K | -32.50%569K | 92.65%-10K | 210.39%372K | 52.38%-60K | 109.56%244K | 620.51%843K | -216.28%-136K | 79.25%-337K | 87.41%-126K |
Net income from continuing operations | -12.80%-3.82M | -25,150.00%-501K | -160.65%-2.42M | 60.77%-346K | 65.00%-553K | 76.46%-3.39M | -98.15%2K | -66.97%-930K | 92.97%-882K | -13.34%-1.58M |
Operating gains losses | 42.86%110K | 171.93%155K | -1,037.50%-75K | -4.55%-23K | 55.88%53K | -99.27%77K | 246.15%57K | 102.42%8K | -100.20%-22K | 113.49%34K |
Depreciation and amortization | 6.88%1.21M | 2.68%307K | 3.73%306K | 16.28%300K | 6.03%299K | 47.27%1.13M | 12.41%299K | 13.03%295K | 24.04%258K | 705.71%282K |
Other non cash items | -63.58%464K | -18.49%291K | -113.42%-71K | --376K | ---132K | -3.70%1.27M | --357K | --529K | ---- | ---- |
Change In working capital | -50.97%304K | 156.99%155K | 9.30%-78K | 230.23%426K | -123.44%-199K | 160.67%620K | 55.77%-272K | -138.22%-86K | 115.87%129K | 369.06%849K |
-Change in receivables | -31.69%819K | 29.96%-1.48M | 93.49%-19K | -59.42%153K | -32.91%2.17M | 126.43%1.2M | 43.92%-2.12M | -161.22%-292K | 127.16%377K | 2,097.28%3.23M |
-Change in inventory | --0 | 80.00%-19K | 0.00%4K | 14.29%8K | -74.07%7K | -96.55%-57K | -258.33%-95K | 104.88%4K | -63.16%7K | 203.85%27K |
-Change in prepaid assets | 1,177.78%115K | 242.86%60K | 60.00%8K | -37.50%55K | 80.95%-8K | 111.69%9K | 4.55%-42K | -88.64%5K | 319.05%88K | 57.14%-42K |
-Change in payables and accrued expense | -18.64%-630K | -19.43%1.6M | -136.04%-71K | 161.22%210K | 0.04%-2.37M | -114.66%-531K | -36.95%1.98M | 192.06%197K | -164.11%-343K | -1,597.47%-2.37M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 256.97%871K | -32.50%569K | 92.65%-10K | 210.39%372K | 52.38%-60K | 109.56%244K | 620.51%843K | -216.28%-136K | 79.25%-337K | 87.41%-126K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 51.88%-575K | -93.04%-222K | 27.03%-162K | 65.82%-81K | 82.29%-110K | 84.84%-1.2M | 16.06%-115K | -91.38%-222K | 96.88%-237K | -2,487.50%-621K |
Capital expenditure reported | 25.55%-504K | -68.32%-170K | 21.18%-160K | 60.51%-77K | 45.51%-97K | -186.86%-677K | 7.34%-101K | -59.84%-203K | ---195K | ---178K |
Net PPE purchase and sale | 80.00%-7K | --0 | 75.00%-2K | 72.73%-3K | 84.62%-2K | ---35K | ---3K | ---8K | ---11K | ---13K |
Net intangibles purchase and sale | 80.65%-12K | --0 | --0 | 90.91%-1K | 64.52%-11K | -55.00%-62K | -57.14%-11K | -12.50%-9K | -1,000.00%-11K | -29.17%-31K |
Net business purchase and sale | 85.67%-52K | ---52K | --0 | --0 | --0 | 95.16%-363K | --0 | --0 | --0 | ---363K |
Net other investing changes | ---- | ---- | ---- | ---- | ---- | 58.57%-58K | --0 | -110.53%-2K | ---20K | ---36K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 51.88%-575K | -93.04%-222K | 27.03%-162K | 65.82%-81K | 82.29%-110K | 84.84%-1.2M | 16.06%-115K | -91.38%-222K | 96.88%-237K | -2,487.50%-621K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -197.16%-616K | 72.32%-178K | -118.68%-125K | -211.89%-207K | -125.06%-106K | -85.67%634K | -144.49%-643K | 555.88%669K | -95.93%185K | 1,075.00%423K |
Net issuance payments of debt | -183.33%-500K | 80.00%-125K | -118.52%-125K | -171.43%-125K | -133.33%-125K | 408.47%600K | 66.79%-625K | -66.25%675K | --175K | --375K |
Net common stock issuance | -95.71%3K | ---17K | --0 | --0 | -59.18%20K | -98.39%70K | --0 | 105.17%9K | -99.74%12K | --49K |
Net other financing activities | -230.56%-119K | -100.00%-36K | --0 | -4,000.00%-82K | 0.00%-1K | -5.88%-36K | ---18K | ---15K | 33.33%-2K | 96.77%-1K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -197.16%-616K | 72.32%-178K | -118.68%-125K | -211.89%-207K | -125.06%-106K | -85.67%634K | -144.49%-643K | 555.88%669K | -95.93%185K | 1,075.00%423K |
Net cash flow | ||||||||||
Beginning cash position | -9.26%3.1M | -13.20%2.61M | 7.53%2.9M | -8.65%2.82M | -9.26%3.1M | -63.80%3.41M | -18.60%3.01M | -28.10%2.7M | -63.42%3.09M | -63.80%3.41M |
Current changes in cash | -0.95%-320K | 98.82%169K | -195.50%-297K | 121.59%84K | 14.81%-276K | 94.73%-317K | 130.04%85K | 645.61%311K | 91.69%-389K | 67.24%-324K |
Effect of exchange rate changes | 4,700.00%48K | 1,366.67%44K | 800.00%7K | -300.00%-2K | 50.00%-1K | --1K | --3K | ---1K | --1K | ---2K |
End cash Position | -8.79%2.82M | -8.79%2.82M | -13.20%2.61M | 7.53%2.9M | -8.65%2.82M | -9.26%3.1M | -9.26%3.1M | -18.60%3.01M | -28.10%2.7M | -63.42%3.09M |
Free cash flow | 165.66%348K | -45.19%399K | 51.69%-172K | 152.53%291K | 51.15%-170K | 81.25%-530K | 72,700.00%728K | -100.00%-356K | 65.91%-554K | 66.05%-348K |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |